Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.verified

XERS

Price:

$6.72

Market Cap:

$1.12B

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its pr...[Read more]

Industry

Biotechnology

IPO Date

2018-06-21

Stock Exchange

NASDAQ

Ticker

XERS

The Enterprise Value as of December 2025 (TTM) for Xeris Biopharma Holdings, Inc. (XERS) is 1.31B

According to Xeris Biopharma Holdings, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.31B. This represents a change of 58.42% compared to the average of 828.80M of the last 4 quarters.

Xeris Biopharma Holdings, Inc. (XERS) Historical Enterprise Value (quarterly & annually)

How has XERS Enterprise Value performed in the past?

The mean historical Enterprise Value of Xeris Biopharma Holdings, Inc. over the last ten years is 257.86M. The current 1.31B Enterprise Value has changed 50.82% with respect to the historical average. Over the past ten years (40 quarters), XERS's Enterprise Value was at its highest in in the March 2025 quarter at 1.05B. The Enterprise Value was at its lowest in in the June 2018 quarter at -36055595.08.

Quarterly (TTM)
Annual

Average

257.86M

Median

229.55M

Minimum

-1034330.94

Maximum

697.39M

Xeris Biopharma Holdings, Inc. (XERS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Xeris Biopharma Holdings, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 89.21%

Maximum Annual Enterprise Value = 697.39M

Minimum Annual Increase = -18561.79%

Minimum Annual Enterprise Value = -1034330.94

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2024697.39M43.71%
2023485.28M89.21%
2022256.48M1.64%
2021252.35M9.93%
2020229.55M12.09%
2019204.78M7.24%
2018190.96M-18561.79%
2017-1034330.94-120.75%

Xeris Biopharma Holdings, Inc. (XERS) Average Enterprise Value

How has XERS Enterprise Value performed in the past?

The current Enterprise Value of Xeris Biopharma Holdings, Inc. (XERS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

479.71M

5-year avg

384.21M

10-year avg

257.86M

Xeris Biopharma Holdings, Inc. (XERS) Enterprise Value vs. Peers

How is XERS’s Enterprise Value compared to its peers?

Xeris Biopharma Holdings, Inc.’s Enterprise Value is less than Immunocore Holdings plc (1.57B), less than Sionna Therapeutics, Inc. (1.79B), greater than AbCellera Biologics Inc. (1.15B), greater than Biohaven Ltd. (1.14B), less than Vera Therapeutics, Inc. (2.75B), less than Celldex Therapeutics, Inc. (1.95B), greater than Janux Therapeutics, Inc. (960.68M), less than BioCryst Pharmaceuticals, Inc. (2.30B), less than Maze Therapeutics, Inc. (1.76B), less than Harmony Biosciences Holdings, Inc. (1.72B),

Build a custom stock screener for Xeris Biopharma Holdings, Inc. (XERS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xeris Biopharma Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xeris Biopharma Holdings, Inc. (XERS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xeris Biopharma Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Xeris Biopharma Holdings, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Xeris Biopharma Holdings, Inc. (XERS)?

What is the 3-year average Enterprise Value for Xeris Biopharma Holdings, Inc. (XERS)?

What is the 5-year average Enterprise Value for Xeris Biopharma Holdings, Inc. (XERS)?

How does the current Enterprise Value for Xeris Biopharma Holdings, Inc. (XERS) compare to its historical average?